Wuxi PharmaTech is anchor investor in the fund, which will target early-stage life science and healthcare investments in China and the US.

WuXi Healthcare Ventures, the corporate venturing arm of China-based medical research firm WuXi PharmaTech, closed its WuXi Healthcare Ventures II, L.P. fund at $290m yesterday, exceeding its $200m target.

WuXi Healthcare Ventures acts an early-stage venture capital firm, backing China and US-based life science and healthcare companies, and operating out of offices in Boston and Shanghai.

WuXi PharmaTech said in July this year it would commit $50m to the fund as anchor investor. The firm plans to invest at…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?